Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Nov 14, 2024
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025
Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M
Read more at globenewswire.com
